fto-in-1

UUN44923 is a FTO inhibitor. It may be useful for treating diseases assocd. with FTO targets, obesity, metabolic syndrome (MS) , type 2 diabetes (T2D) , Alzheimer's diseases, breast cancers, small- cell lung cancers, a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma and the like.

FTO-IN-1 TFA is an inhibitor of adiposity and obesity-related enzymes (FTO) (IC50 < 1 μM).FTO-IN-1 TFA can be used to study cancer.

FTO-IN-10 (compound 7), a potent inhibitor of the human demethylase FTO (fat mass and obesity-associated protein), exhibits an IC50 of 4.5 μM. It interacts with the binding pocket of FTO's structural domain II via hydrophobic and hydrogen bonding interactions, and promotes DNA damage and autophagic cell death in A549 cells [1].

FTO-IN-13 (compound 8t) is a potent FTO inhibitor with antiproliferative properties. It induces apoptosis (cell apoptosis) and reduces the expression of Bcl-2 and Caspase 3 active proteins. Additionally, FTO-IN-13 lowers the expression of MYC and CEBPA genes and demonstrates anticancer activity.

FTO-IN-14 (Compound F97) is an inhibitor of the RNA demethylase Fat mass and obesity-associated protein (FTO), with an IC50 of 0.45 μM. It modulates the expression of the ASB2, RARA, and MYC proteins. FTO-IN-14 demonstrates antiproliferative activity in AML cancer cells, with IC50 values of 0.7-5.5 μM against MOLM13, NB4, HEL, OCI-AML3, MV4-11, and MONOMAC6, and induces apoptosis in NB4 cells. Additionally, FTO-IN-14 exhibits antitumor activity in a mouse NB4 xenograft model.

FTO-IN-12 (Compound 2), an inhibitor of fat mass and obesity-related protein (FTO), exhibits Kd and IC50 values of 185 nM and 1.46 μM, respectively. This compound is utilized in researching neurodegenerative diseases.

Radicicol (Monorden) is an antifungal antibiotic and a potent inhibitor of heat shock protein 90 (Hsp90), which leads to the degradation of Hsp90 by the proteasome by binding to its ATP-binding pocket. In addition, Radicicol inhibits the growth and proliferation of several tumor cell lines. It also has anti-malarial activity and acts as an inhibitor of adipose- and obesity-related proteins (FTO). Radicicol inhibits iNOS gene expression by blocking the p38 kinase signaling pathway and NF-kB/Rel

PROTACFTO degrader 1 is a PROTAC designed to target and degrade fat mass and obesity-associated protein (FTO). It leverages the VHL E3 ligase and the ubiquitin-proteasome system for the selective degradation of FTO. This compound enhances m6A modifications on mRNAs related to ribosome biogenesis and promotes their YTHDF2-mediated degradation. Furthermore, PROTACFTO degrader 1 effectively inhibits cancer cell proliferation and induces apoptosis, making it a valuable candidate for cancer research, particularly in acute myeloid leukemia (AML).

FTO ligand-1 is a component of the FTOPROTAC degrader FP54, serving as an FTO ligand. It effectively inhibits cell proliferation and prevents FTO degradation induced by FP54. FTO ligand-1 is applicable in cancer research, particularly in studies related to acute myeloid leukemia (AML).

FTO-IN-8, also known as FTO-43, is an inhibitor of N6-methyladenosine demethylase FTO (fat mass- and obesity-associated protein). It exhibits an IC50 value of 5.5 μM and displays anti-cancer cell proliferative activity [1].